Search

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic atrophy. [ABSTRACT FROM AUTHOR]

After an FDA rejection last year, Aldeyra has scored a(nother) phase 3 win for dry eye drug reproxalap. [ABSTRACT FROM AUTHOR]

Oculis is advancing its precision medicine approach to dry eye disease, outlining plans to finalize a phase 3 study after seeing signs of efficacy. [ABSTRACT FROM AUTHOR]

Palatin has some changes to make for the upcoming trials of the dry eye disease drug PL9643 after the phase 3 MELODY-1 study failed on the main goal. [ABSTRACT FROM AUTHOR]

The lead candidate in the acquired pipeline met the primary phase 3 endpoint, positioning Alcon to file for FDA approval in the middle of the year. [ABSTRACT FROM AUTHOR]

Aldeyra Therapeutics had prepared for the worst and now it's here. The FDA has rejected the dry eye drug reproxalap. [ABSTRACT FROM AUTHOR]

Aldyera's shares fell more than 60% after the biotech indicated the FDA could soon reject its dry eye disease med due to a lack of convincing data. [ABSTRACT FROM AUTHOR]

A widely-available probiotic showed benefits in a mouse model of dry eye disease, adding yet another potential indication for microbiome medicine. [ABSTRACT FROM AUTHOR]

Aldeyra has notched up another phase 3 win for its allergic conjunctivitis treatment, as the biotech awaits an FDA decision for dry eye disease. [ABSTRACT FROM AUTHOR]

Varenicline nasal spray is indicated to treat the signs and symptoms of dry eye disease. [ABSTRACT FROM AUTHOR]

Oyster Point Pharma is powering ahead with plans to lay off 50 employees as part of cost-cutting measures to claw back $16 million by the end of 2023. [ABSTRACT FROM AUTHOR]

Aldeyra's dry med was successful in a crossover trial, another clinical win as the company nears a formal approval submission. [ABSTRACT FROM AUTHOR]

Aldeyra Therapeutics' late-study primary endpoint switch has paid off. [ABSTRACT FROM AUTHOR]

Aldeyra Therapeutics' dry eye drug helped relieve ocular redness in a phase 2 trial but merely "approached statistical significance" on a secondary endpoint of wetness in the eye. We know you're here for the unspun version of this story, and this is it: the secondary goal was not met. [ABSTRACT FROM AUTHOR]

Patients with dry eye disease taking Bausch + Lomb and Novaliq's eye drop saw an improvement in the severity of eye dryness and damage to the eye during a phase 3 clinical trial. [ABSTRACT FROM AUTHOR]

Maybe primary endpoints matter after all. Days after dismissing the importance of a midphase flop, Aerie Pharmaceuticals CEO Vicente Anido has left the company, leaving an interim leader to pursue what he claimed was "a clear path toward approval." [ABSTRACT FROM AUTHOR]

Aerie Pharmaceuticals earned the ire of Bio Twitter and its investors Wednesday night after it dropped a failed midstage study after-hours, but whitewashed the flop and said it would still push on with a phase 3. [ABSTRACT FROM AUTHOR]

Novartis is culling an eye disease asset but has got an FDA approval date for its troubled The Medicines Company heart drug, while also sending off for review its Bosulif-rivalling blood cancer hopeful. [ABSTRACT FROM AUTHOR]

Tarsus Pharmaceuticals met all primary and secondary endpoints in a pivotal phase 2b/3 trial of its eyedrop treatment for eyelid mange, and expects to file for regulatory approval next year following results of another pivotal study already underway. [ABSTRACT FROM AUTHOR]

Aurinia and its dry eye drug started 2019 with a mixed bag of data from a head-to-head trial with Allergan's blockbuster Restasis. Now, it's unveiling results from a different trial—and they're definitely not mixed. The company is abandoning the dry eye program after it failed to beat placebo at helping patients produce more tears. [ABSTRACT FROM AUTHOR]

Doctors may prescribe steroids or eye drops for patients with dry eye disease. But Azura Ophthalmics wants to do one better with a drug that tackles the root cause of the disease. To that end, it's raised $20 million, which will bankroll a pivotal trial in the first quarter of 2021. [ABSTRACT FROM AUTHOR]

Leaning into its new name, Bausch Health is laying the groundwork for a pipeline expansion. It's forking over $10 million upfront for the option to acquire Allegro Ophthalmics' eye disease assets, including its retinal disease med risuteganib. If Allegro pulls off another financing, Bausch will hand over the remaining $40 million, likely in 2021. [ABSTRACT FROM AUTHOR]

Aldeyra Therapeutics has halted clinical development of two systemic disease programs to stretch out its cash runway to the end of next year. The action is intended to enable Aldeyra keep pushing its ocular disease programs through late-phase development despite its falling cash reserves. [ABSTRACT FROM AUTHOR]

Welcome to our pre-Christmas news of note, as we gather up bite-size news from around biotech. [ABSTRACT FROM AUTHOR]